Oncopeptides (STO: ONCO)

Last close As at 09/10/2025

SEK5.41

−0.20 (−3.57%)

Market capitalisation

SEK1,449m

Oncopeptides is a Swedish biotech company developing peptide-drug conjugates for the treatment of hematological cancers, with a focus on relapsed or refractory multiple myeloma.

Latest Insights

Healthcare | Non client QV

Oncopeptides — Targeted oncology with commercial momentum

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Sofia Heigis

    CEO

  • Henrik Bergentoft

    CFO

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free